key: cord-0942131-gjctfjub authors: Ahmad, Imran; Azam Rathore, Farooq title: Neurological manifestations and complications of COVID-19: A Literature Review date: 2020-05-06 journal: J Clin Neurosci DOI: 10.1016/j.jocn.2020.05.017 sha: 25454077befb0db9f4580624419d6e1ca49c8299 doc_id: 942131 cord_uid: gjctfjub Abstract The Coronavirus disease due to SARS-CoV-2 emerged in Wuhan city, China in December 2109 and rapidly spread to more than 200 countries as a global health pandemic. There are more than 2.3 million confirmed cases and around 165,000 fatalities. The primary manifestation is respiratory and cardiac but neurological features are also being reported in the literature as case reports and case series. The most common reported symptoms to include headache and dizziness followed by encephalopathy and delirium. Among the complications noted are Cerebrovascular accident, Guillian barre syndrome, acute transverse myelitis, and acute encephalitis. The most common peripheral manifestation was hyposmia. It is further noted that sometimes the neurological manifestations can precede the typical features like fever and cough and later on typical manifestations develop in these patients. Hence a high index of suspicion is required for timely diagnosis and isolation of cases to prevent the spread in neurology wards. We present a narrative review of the neurological manifestations and complications of COVID-19. Our aim is to update the neurologists and physicians working with suspected cases of COVID-19 about the possible neurological presentations and the probable neurological complications resulting from this novel virus infection. The Novel Coronavirus (COVID- 19) outbreak originated from the Wuhan city, China in December 2019 1 , 2 Chinese authorities reported unusual cases of pneumonia with an undetermined etiology. 3 Initially all cases were clustered to the Huanan seafood wholesale market. World Health Organization (WHO) declared it a pandemic on 11 March 2020. 4 As of 19 th April 2020, there are more than 2.3 million confirmed case of COVID-19 with 162,000 fatalities in the world. 5 COVID-19 has generated a great interest among physicians, scientists, and researchers all around the globe. 6 The amount of research and number of articles being published on COVID-19 is unprecedented. It has been estimated that hundreds of manuscripts have been published on this topic since the start of the year. 7 Data on different aspects of the disease manifestations, pathology, transmission, prevention, and management strategies has started emerging 8, 9, 10 Although COVID-19 preferentially affects the respiratory and cardiovascular system, however, severe patients with COVID-19 are also likely to have neurological symptoms (such as headache, dizziness, hypogeusia, and neuralgia) and complications including encephalopathy, acute cerebrovascular diseases, impaired consciousness and skeletal muscular injury. 11 , 12 We present a narrative review of the neurological manifestations and complications of COVID-19. Our aim is to update the neurologists and physicians working with suspected cases of COVID-19 about the possible neurological presentations and the probable neurological complications resulting from this novel virus infection. We searched Medline, PubMed Central and Google Scholar using keywords " COVID-19", "Coronavirus", "pandemic", "SARS-COV-2", "neurology", "neurological", "complications", "manifestations" and "complications". Search was limited only to English language manuscripts with no time limit. The literature search was last done on 11 th April 2020. It is important to note that new data is being shared regularly and so far, it consists mostly of pre-prints, case reports, small case series, and part of an article describing clinical features of COVID-19. Most of the data on COVID-19 at present is being published from China. 13 At the time of writing this article we were able to locate only 2 full text articles in English biomedical literature specifically describing the neurological manifestations and complications in COVID-19 in detail. There is not enough experimental data available for COVID-19, but it is considered a mutation of Severe Acute Respiratory Syndrome and Middle East Respiratory syndrome. 14 Therefore, it is expected that it will behave in a similar manner. 15 Corona viruses are not primarily neurotropic virus and their primary target is respiratory epithelium. The target receptor for attachment to cell and subsequent internalization is through the angiotensin converting enzyme-2 receptor (ACE 2). After entry into the cell the virus RNA is released in the cytoplasm subsequently translated and replicated, after formation of envelope protein and incorporation of RNA into it the virus is released in the circulation. 16 ACE 2 receptors are also found in glial cells in brain and spinal neurons. Hence it can attach, multiply and damage the neuronal tissue. There is evidence from the animal experiments in mice that coronavirus enters the brain through a retrograde transfer via the olfactory epithelium or through the cribriform bone and reaches the brain in seven days' time. Secondly, during the viremia phase of illness, disruption of blood brain barrier causes the virus to enter the brain directly. Another postulated mechanism is the invasion of peripheral nerve terminals by CoV which then gains entry to the CNS through the synapse connected route. SinceCOVID-19 has similarities with Severe Acute Respiratory Syndrome, therefore it can be presumed that it also follows the same pathways for CNS invasion as discussed above. The detailed discussion of host and virus interaction is beyond the scope of this article, and has been published elsewhere. 15, 16 Neuropathological Mechanism of CNS damage COVID-19 results in neurological damage likely by two mechanisms; hypoxic brain injury and an immune mediated damage to the CNS. Severe pneumonia can result in systemic hypoxia leading to brain damage. The contributory factors include peripheral vasodilatation, hypercarbia, hypoxia and anaerobic metabolism with accumulation of toxic compounds. These can result in neuronal swelling and brain edema which ultimately results in neurological damage. 9 2. Immune mediated injury Immune mediated injury is mainly due to the cytokine storms with increased levels of inflammatory cytokines and activation of T lymphocytes, macrophages, and endothelial cells. Further release of Interleukins 6 causes vascular leakage, activation of complement and coagulation cascade, disseminated intravascular coagulation and end organ damage. 17 The important neurological manifestations and complications of COVID-19 reported in literature so far are summarized in Table 1 The second article is a prospective case series of 58 patients from France. 12 The median age of patients was 63 years and neurological complications were seen in a higher percentage 49/58 (84%). As assessed by confusion Assessment method for intensive care unit CAM-ICU scale , agitation was the most common symptoms 40/58 (69%) followed by confusion 26/40 (65%).Corticospinal tract signs were present in in 39/58 (67% )and a dysexecutive syndrome at the time of discharge was noted in14/39 (36%). Table 1 shows the comparison between the two study cohorts. The neurological manifestations and complications of COVID-19 can be divided into central and peripheral as discussed below. Table 2 Central Nervous System Manifestations Encephalopathy Mao et al reported headache and encephalopathy in 40% of patients in their cohort but the details and the diagnostic criteria used was not described. 11 Filatove et al reported a case of a 74-year-old male with past medical history of atrial fibrillation, stroke, Parkinson disease, chronic obstructive pulmonary disease, and recent cellulitis, who presented to the emergency department with fever and cough. 19 Initial diagnostic work up did not suggest any serious issue and he was discharged to home. He reported back with worsening symptoms, including headache, altered mental status, fever, and cough. Chest X ray was suggestive of pneumonia, while CT scan brain was unremarkable except for signs of previous stroke. PCR assay of CSF was negative for infection. He patients from China, documented hypoxic encephalopathy in 20 patients. 20 The incidence was significantly lower in the patients who had recovered. Poyiadji and colleagues reported the first case of COVID-19-associated acute hemorrhagic necrotizing encephalopathy (ANE) from USA. 21 A female patient in her late fifties presented with a 3-day history of cough, fever, and altered mental status. Polymerase chain reaction (PCR) assay was positive for COVID-19 and negative for Herpes Simplex Virus 1 and 2, West Nile and Varicella Zoster Virus. Non contrast head CT images demonstrated symmetric hypoattenuation within the bilateral medial thalami with a normal CT angiogram and CT venogram. MRI brain demonstrated hemorrhagic rim enhancing lesions within the bilateral thalami, medial temporal lobes, and sub insular regions. She was started on intravenous Immunoglobulin (IVIG), but the outcome was not mentioned. ANE is a rare complication of viral infections like influenza. The proposed mechanism is likely due to cytokine storm which results in disruption of blood brain barrier and damage to the brain parenchyma. He was treated empirically with IVIG, steroids, antibiotics and antiviral. The response to treatment was good and he was discharged to an isolation facility for further rehabilitation.The authors attributed acute myelitis to the cytokine storm and overactive inflammatory response as evident by high levels of serum ferritin, C-reactive protein, Serum Amyloid-A and Interleukin 6 levels. A major limitation of this case report is the lack of CSF PCR for coronavirus and MRI imaging of spine due to epidemic in Wuhan city. Sharifi et al from Iran reported case of intracranial bleed resulting in CVA in a 79 Years old COVID-19 positive male. 23 He was admitted in the emergency in a semi-conscious state (Glasgow Coma Scale 7/15)with history of fever and cough. On examination there was, bilateral extensor planter response with coarse crepitation in left lower zones. PCR assay from nasopharyngeal secretion was positive for COVID-19. CT scan chest showed ground glass opacity suggestive of viral pneumonia. CT scan brain revealeda massive bleed within the right hemisphere with intraventricular and subarachnoid extension. This gentleman was neither a known hypertensive nor on any anticoagulants that could have caused this event. The platelets and PT/INR on admission were normal. The authors postulated that probably dysregulation in the ACE 2 receptors lead to cerebral auto regulation, sympatho-adreanl system and cerebral blood flow could have resulted in the bleed. Another aspect that is difficult to explain is the near normal blood pressure in this case at the time of admission. Mao and colleagues reported six case of CVA in their cohort of 214. 11 There were five ischemic and one case of hemorrhagic stroke. The French cohort had three cases of ischemic strokes which were detected on neuroimaging when the patients underwent imaging for encephlaophathy. 12 The patients did not have focal neurological signs. Probably the symptoms were masked due to presence of encephalopathy, but it highlights the importance of neuroimaging in evaluation of such cases. However more evidence is needed to establish a causal relationship between stroke and COVID-19. Moriguchi et all reported first confirmed case of COVID-19 associated viral encephalitis from Japan. 24 A 24 Years old man presented with fever followed by seizure and unconsciousness. He had neck stiffness and underwent CT scan brain which was normal. There was patchy pneumonia on CT chest. PCR assay from nasopharyngeal Headaches and dizziness are a nonspecific and minor symptoms of many diseases. They have been reported as minor symptoms associated with presentation of COVID-19 in different reports. The incidence rages from 3-12.1 %. 25, 26, 27 The detailed mechanism and pathophysiology has not been discussed in any of these reports Mao et al reported skeletal muscle injury in 17 [19.3%] patients in the severely ill and 6 [4.8%] patients in the non-severe group. 11 They defined skeletal muscle injury as patient having myalgia and elevated serum creatine kinase level above 200 U/L. They concluded that it was not clear whether this was due to the direct effect of virus on muscle tissue. The other possible mechanism proposed was the infection-mediated immune response that causing elevated pro-inflammatory cytokines in serum resulting in skeletal muscle damage. However, it is important to note that patients in the severely ill group in addition to raised muscle enzymes , also had elevated liver enzymes and deranged renal functions which could have contributed to the this clinical picture . Moreover, no specific diagnostic workup for confirmation like NCS/EMG or muscle histopathology was performed. Therefore, it is difficult to exclude that these patients might be having critical illness myopathy and neuropathy in addition to skeletal muscle damage. Mao et al also reported neuralgia in five patients and epilepsy and ataxia in one each, but further details were not mentioned. 11 COVID-19 primarily affects the respiratory and cardiovascular system. However, neurological involvement is not uncommon and can result in serious complications if not detected and managed early. These complications are mostly seen in severely ill patients and in some cases can even precede the respiratory symptoms or many be the only symptoms in COVID-19 patients. Therefore, a high index of suspicion is required while dealing with such cases for prompt treatment and prevention. It is also important to systematically collect data on the short and long term neurological complications from different parts of the world and to document the functional outcomes after these complications. Highlights  COVID-19 primarily affects the lungs and respiratory system  Some patients may present with neurological symptoms  Most common CNS manifestations include headache, dizziness and encephalopathy.  Most frequently reported PNS manifestations include loss of smell and taste which may be a presenting symptom as well.  Neurological complications are more common in severely ill COVID-19 patients. A Novel Coronavirus from Patients with Pneumonia in China World Health Organization. Pneumonia of unknown cause -China. Disease outbreak news WHO Director-General's opening remarks at the media briefing on World Health Organization Publishing research during pandemics: are you vulnerable to the COVID-19 or predatory publishers? COVID-19) Current Status and Future Perspectives: A Narrative Review The epidemiological and clinical features of COVID-19 and lessons from this global infectious public health event Molecular immune pathogenesis and diagnosis of COVID-19 Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease Neurologic Features in Severe SARS-CoV-2 Infection Coronavirus disease 2019: a bibliometric analysis and review Nervous system involvement after infection with COVID-19 and other coronaviruses The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host Virus Interaction, and Proposed Neurotropic Mechanisms HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression Cytokine storms in COVID-19 cases? Tidsskr Nor Laegeforen Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features Acute myelitis after SARS-CoV-2 infection: a case report. medRxiv COVID 19 and intra cerebral hemorrhage: causative or coincidental A first case of meningitis/encephalitis associated with SARS-Coronavirus-2 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of metaanalysis Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms. Int Forum Allergy Rhinol Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol Guillain Barre syndrome associated with COVID-19 infection: A case report Syndrome associated with SARS-CoV-2 infection. IDCases Guillain-Barré Syndrome Associated with SARS-CoV-2